Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience

PURPOSE: Dramatic advances in our understanding of the molecular pathophysiology of cancer, along with a rapidly expanding portfolio of molecular targeted drugs, have led to a paradigm shift toward personalized, biomarker-driven cancer treatment. Here, we report the 2-year experience of the Comprehe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Hoefflin, Rouven, Geißler, Anna-Lena, Fritsch, Ralph, Claus, Rainer, Wehrle, Julius, Metzger, Patrick, Reiser, Meike, Mehmed, Leman, Fauth, Lisa, Heiland, Dieter Henrik, Erbes, Thalia, Stock, Friedrich, Csanadi, Agnes, Miething, Cornelius, Weddeling, Britta, Meiss, Frank, von Bubnoff, Dagmar, Dierks, Christine, Ge, Isabell, Brass, Volker, Heeg, Steffen, Schäfer, Henning, Boeker, Martin, Rawluk, Justyna, Botzenhart, Elke Maria, Kayser, Gian, Hettmer, Simone, Busch, Hauke, Peters, Christoph, Werner, Martin, Duyster, Justus, Brummer, Tilman, Boerries, Melanie, Lassmann, Silke, von Bubnoff, Nikolas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446498/
https://ncbi.nlm.nih.gov/pubmed/32913998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados